A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex

Molecular Cancer Therapeutics

Volumn 5, Issue 2, 2006, Pages 287-295

  Marchand, Christophe ^a   Antony, Smitha ^a   Kohn, Kurt W ^a   Cushman, Mark ^b   Ioanoviciu, Alexandra ^b   Staker, Bart L ^c   Burgin, Alex B ^c   Stewart, Lance ^c   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c DeCODE Chemistry & Biostructures   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMANITIN; BREFELDIN A; CAMPTOTHECIN DERIVATIVE; CARBAZOLE DERIVATIVE; COLCHICINE; CYCLOSPORIN; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; EPOTHILONE A; FORSKOLIN; FUSICOCCIN; FUSIDIC ACID; ISOQUINOLINE DERIVATIVE; MJ 238; MOCIMYCIN; PACLITAXEL; RAPAMYCIN; RAZOXANE; SA 315 F; THIOSTREPTON; TOPOTECAN; TSUKUBAENOLIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BASE PAIRING; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DNA FLANKING REGION; DRUG BINDING; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; HUMAN; INTERCALATION COMPLEX; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; X RAY CRYSTALLOGRAPHY;

CAMPTOTHECIN; CRYSTALLOGRAPHY; DNA; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; HUMANS; HYDROGEN BONDING; INDENES; ISOQUINOLINES; MOLECULAR STRUCTURE; TOPOTECAN;

EID: 33644970269     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0456     Document Type: Article

References (66)

1. Lee MP, Brown SD, Hsieh T-S. DNA topoisomerase I is essential in Drosophila melanogaster. Proc Natl Acad Sci U S A 1993;90:6656-60.
2. Morham S, Kluckman KD, Voulomanos N, Smithies O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol Cell Biol 1996;16:6804-9.
3. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
4. Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco G. Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat 1999;2: 307-18.
5. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:83-105.
6. Champoux JJ. DNA TOPOISOMERASES: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
7. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002;3:430-40.
8. Stewart L, Redinbo MR, Qiu X, Hol WGJ, Champoux JJ. A model for the mechanism of human topoisomerase I. Science 1998;279:1534-41.
9. Wall ME, Wani MC. Camptothecin and Taxol: discovery to clinic-thirteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1995;55: 753-60.
10. Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988;34:755-60.
11. Nitiss J, Wang JC. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci U S A 1988;85:7501-5.
12. Bjornsti M-A, Benedetti P, Viglianti GA, Wang JC. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 1989;49:6318-23.
13. Jaxel C, Kohn KW, Wani MC, Wall ME, Pommier Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 1989;49:1465-9.
14. Jaxel C, Capranico G, Kerrigan D, Kohn KW, Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem 1991;266:20418-23.
15. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002;99:15387-92.
16. Staker BL, Feese MD, Cushman M, et al. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005;48:2336-45.
17. Meng L-H, Liao Z-H, Pommier Y. Non-camptothecin DNA topoisomerase I inhibitors in cancer chemotherapy. Curr Top Med Chem 2003;3:305-20.
18. Pizzolato JF, Saltz LB. The camptothecins. Lancet 2003;361:2235-42.
19. Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: current perspectives. Bioorg Med Chem 2004;12:1585-604.
20. Burke TG, Mi ZM. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 1994; 37:40-6.
21. Brangi M, Litman T, Ciotti M, et al. Camptothecin resistance: role of the ATP binding cassette (ABC) half-transporter, mitoxantrone-resistance (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 1999;59:5938-46.
22. Kohlhagen G, Paull K, Cushman M, Nagafufuji P, Pommier Y. Protein-linked DNA strand breaks induced by NSC 314622, a non-camptothecin topoisomerase I poison. Mol Pharmacol 1998;54:50-8.
23. Antony S, Jayaraman M, Laco G, et al. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I. Cancer Res 2003;63:7428-35.
24. Ioanoviciu A, Antony S, Pommier Y, Staker BL, Stewart L, Cushman M. Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis. J Med Chem 2005;48:4803-14.
25. Chrencik JE, Staker BL, Burgin AB, et al. Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol 2004;339: 773-84.
26. Pommier Y, Cherfils J. Interfacial protein inhibition: a nature's paradigm for drug discovery. Trends Pharmacol Sci 2005;28:136-45.
27. Pommier Y, Marchand C. Interfacial inhibitors of protein-nucleic acid interactions. Curr Med Chem Anti-Canc Agents 2005;5:421-9.
28. Stewart L, Ireton G, Parker L, Madden KR, Champoux JJ. Biochemical and Biophysical analyses of recombinant forms of human topoisomerase I. J Biol Chem 1996;271:7593-601.
29. Navaza J. Implementation of molecular replacement in AMoRe. Acta Crystallogr D Biol Crystallogr 2001;57:1367-72.
30. Brunger AT, Adams PD, Clore GM, et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998;54:905-21.
31. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997;53:240-55.
32. McRee DE. XtalView/Xfit-a versatile program for manipulating atomic coordinates and electron density. J Struct Biol 1999;125:156-65.
33. Oldfield TJ. X-LIGAND: an application for the automated addition of flexible ligands into electron density. Acta Crystallogr D Biol Crystallogr 2001;57:696-705.
34. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WGJ. Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998;279:1504-13.
35. Carey JF, Schultz SJ, Sisson L, Fazzio TG, Champoux JJ. DNA relaxation by human topoisomerase I occurs in the closed clamp conformation of the protein. Proc Natl Acad Sci U S A 2003;100: 5640-5.
36. Woo MH, Losasso C, Guo H, Pattarello L, Benedetti P, Bjornsti MA. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality. Proc Natl Acad Sci U S A 2003;100:13767-72.
37. Stewart L, Ireton G, Champoux JJ. The domain organization of human topoisomerase I. J Biol Chem 1996;271:7602-8.
38. Xiao X, Cushman M. Effect of E-ring modifications in camptothecin on topoisomerase I inhibition: a quantum mechanics treatment. J Org Chem 2005;70:9584-7.
39. Pommier Y, Kohlhagen G, Laco GS, Kroth H, Sayer JM, Jerina DM. Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site. J Biol Chem 2002;277:13666-72.
40. Fox BM, Xiao X, Antony S, et al. Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids. J Med Chem 2003;46:3275-82.
41. Xiao X, Antony S, Kohlhagen G, Pommier Y, Cushman M. Novel autoxidative cleavage reaction of 9-fluoredenes discovered during synthesis of a potential DNA-threading indenoisoquinoline. J Org Chem 2004; 69:7495-501.
42. Xiao X, Antony S, Kohlhagen G, Pommier Y, Cushman M. Design, synthesis, and biological evaluation of cytotoxic 11-aminoalkenylindenoisoquinoline and 11-diaminoalkenylindenoisoquinoline topoisomerase I inhibitors. Bioorg Med Chem 2004;12:5147-60.
43. Interthal H, Quigley PM, Hol WG, Champoux JJ. The role of lysine 532 in the catalytic mechanism of human topoisomerase I. J Biol Chem 2004;279:2984-92.
44. Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G, Pommier Y. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Cancer Res 2001; 61:504-8.
45. Capranico G, Kohn KW, Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res 1990;18:6611-9.
46. Strumberg D, Pilon AA, Smith M, Hickey R, Malkas L, Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol 2000;20:3977-87.
47. Staker BL, Feese MD, Cushman M, et al. Structure of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem 2005;48:2336-45.
48. Renault L, Guibert B, Cherfils J. Structural snapshots of the mechanism and inhibition of a guanine nucleotide exchange factor. Nature 2003;426:525-30.
49. Mossessova E, Corpina RA, Goldberg J. Crystal structure of ARF1*Sec7 complexed with brefeldin A and its implications for the guanine nucleotide exchange mechanism. Mol Cell 2003;12:1403-11.
50. Jin L, Harrison SC. Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci U S A 2002; 99:13522-6.
51. Huai Q, Kim HY, Liu Y, et al. Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci U S A 2002;99:12037-42.
52. Kissinger CR, Parge HE, Knighton DR, et al. Crystal structures of human calcineurin and the human FKBP12-506-calcineurin complex. Nature 1995;378:641-4.
53. Griffith JP, Kim JL, Kim EE, et al. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-506 complex. Cell 1995;82:507-22.
54. Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsα. GTPγS. Science 1997;278:1907-16.
55. Wurtele M, Jelich-Ottmann C, Wittinghofer A, Oecking C. Structural view of a fungal toxin acting on a 14-3-3 regulatory complex. EMBO J 2003;22:987-94.
56. Choi J, Chen J, Schreiber SL, Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996;273:239-42.
57. Ravelli RB, Gigant B, Curmi PA, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004; 428:198-202.
58. Gigant B, Wang C, Ravelli RB, et al. Structural basis for the regulation of tubulin by vinblastine. Nature 2005;435:519-22.
59. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E. The binding conformation of Taxol in β-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A 2001; 98:5312-6.
60. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 2004;305:866-9.
61. Agrawal RK, Frank J. Structural studies of the translational apparatus. Curr Opin Struct Biol 1999;9:215-21.
62. Laurberg M, Kristensen O, Martemyanov K, et al. Structure of a mutant EF-G reveals domain III and possibly the fusidic acid binding site. J Mol Biol 2000;303:593-603.
63. Bowen WS, Van Dyke N, Murgola EJ, Lodmell JS, Hill WE. Interaction of thiostrepton and elongation factor-G with the ribosomal protein L11-binding domain. J Biol Chem 2005;280:2934-43. Epub 2004 Oct 18.
64. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A 1994;91:1781-5.
65. Classen S, Olland S, Berger JM. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc Natl Acad Sci U S A 2003;100:10629-34.
66. Bushnell DA, Cramer P, Kornberg RD. Structural basis of transcription: α-amanitin-RNA polymerase II cocrystal at 2.8 A resolution. Proc Natl Acad Sci U S A 2002;99:1218-22.